Dr. Herbst’s primary mission is the enhanced integration of clinical, laboratory, and research programs to bring new treatments to cancer patients. He has led the Phase I development of several of the new generation of targeted agents for non-small cell lung cancer (NSCLC), including gefitinib, erlotinib, cetuximab, and bevacizumab. More recently, he participated in the successful registration of pembrolizumab for the treatment of advanced non-small cell lung cancer, following the successful Yale-led KEYNOTE 10 study of the immune therapy drug commonly used to treat other cancers. He was co-leader for the BATTLE-1 clinical trial program, co-leads the subsequent BATTLE-2 clinical trial program, and served as a Co-program Leader of the Developmental Therapeutics Program for the YCC Support Grant. Dr. Herbst’s laboratory work is focused on immunotherapy angiogenesis; dual epidermal growth factor receptor (EGFR)/vascular endothelial growth factor receptor (VEGFR) inhibition in NSCLC, and targeting KRAS-activated pathways. More recently, he has explored predictive biomarkers for the use of immunotherapy agents. This work has been translated from the preclinical to clinical setting in multiple Phase II and III studies which he has led. After earning a B.S. and M.S. degree from Yale University, Dr. Herbst earned his M.D. at Cornell University Medical College and his Ph.D. in molecular cell biology at The Rockefeller University in New York City, New York. His postgraduate training included an internship and residency in medicine at Brigham and Women’s Hospital in Boston, Massachusetts. His clinical fellowships in medicine and hematology were completed at the Dana-Farber Cancer Institute and Brigham and Women’s Hospital, respectively. Subsequently, Dr. Herbst completed a M.S. degree in clinical translational research at Harvard University in Cambridge, Massachusetts. Dr. Herbst is an author or co-author of more than 275 publications, including peer-reviewed journal articles, abstracts, and book chapters. His work has been published in many prominent journals, such as the Journal of Clinical Oncology, Clinical Cancer Research, Lancet, the New England Journal of Medicine, and Nature. His abstracts have been presented at the annual meetings of the American Society of Clinical Oncology (ASCO), the American Association for Cancer Research (AACR), the World Conference on Lung Cancer, the Society of Nuclear Medicine Conference, and the European Organization for Research and Treatment of Cancer. Dr. Herbst was a member of the National Cancer Policy Forum (1998-2014) for which he organized an Institute of Medicine meeting focused on policy issues in personalized medicine. He is a member of ASCO and, as a member of AACR, he chairs the Tobacco Task Force. He is a fellow of the American College of Physicians and an elected member of the Association of American Physicians. Dr. Herbst is also a member of the medical advisory committee for the Lung Cancer Research Foundation and chair of the communications committee for ASCO and the International Association for the Study of Lung Cancer. He is currently the Vice Chair for Developmental Therapeutics for the Southwestern Oncology Group (SWOG) Lung Committee, Principal Investigator of the SWOG 0819 trial, and steering committee chair for the Lung Master Protocol (Lung MAP). Dr. Herbst was awarded the 2010 Waun Ki Hong Award for Excellence in Team Science by the Division of Cancer Medicine, UT-MDACC. The Alvin S. Slotnick Lecture Award for notable contributions to lung cancer research was bestowed upon him by Dana-Farber/Brigham and Women’s Cancer Center in 2014. That same year, the Bonnie Addario Foundation honored him with the Annual Addario Lectureship Award and the Bonnie J. Addario Excellence in Collaboration and Innovation Award. In 2015, the Clinical Research Forum presented his project “Predictive Correlates of Response to the Anti-PD-L1 Antibody MPDL3280A in Cancer Patients” its top Clinical Research Achievement Award in the United States for 2015. For his lifetime achievement in scientific contributions to thoracic cancer research, Herbst was awarded the 2016 Paul A. Bunn, Jr. Scientific Award by the International Association for the Study of Lung Cancer at IASLC 17th World Conference on Lung Cancer in Vienna, Austria. His work has been funded by ASCO, AACR, the United States Department of Defense, and the National Cancer Institute. In 2015, his team at Yale was awarded a lung cancer SPORE by the NCI, and he serves as a principal investigator for the AACR/ Stand Up to Cancer Dream Team grant. EDUCATION & TRAINING MMS Harvard University, Clinical Translational Research (1997) MD Cornell University Medical College (1991) PhD Rockefeller University (1990) BS Yale University, Molecular Biophysics & Biochemistry (1984) MS Yale University, Molecular Biophysics and Biochemistry (1984) Fellowship Brigham and Women`s Hospital Fellowship Dana Farber Cancer Institute Residency Brigham and Women`s Hospital HONORS & RECOGNITION Elected to the Association of American Physicians AAP (2015) Addario Foundation Lectureship Award Bonnie Addario Foundation (2014) Alvin S. Slotnick Lecture Award for notable contributions to lung cancer research Dana-Farber/Brigham and Women’s Cancer Center (2014) Best Doctors, New York Magazine (2014) Honorary Professor, University College London Cancer Center University College London (2012) Sikand Orator Yale University (2011) PROFESSIONAL SERVICE National Cancer Institute (2012 - Present) Thoracic Malignancy Steering Committee - National Cancer Institute
Executive Director - Clinical Research PathwaysClinical Research Pathways
IRB, IRBS, Human Research Protection Programs, Expanded Access, Expanded Access Program, FDA, Compassionate Care, clinical trial, Clinical Research, Research Ethics, Clinical Trials
Marjorie A. Speers, Ph.D., is a global leader in human research protections. Most recently, she was the inaugural president and CEO of the Association for the Accreditation of Human Research Protection Programs, Inc. (AAHRPP), retiring in 2013. Dr. Speers views the opportunity to lead this one-of-a-kind foundation—and continue to contribute to research protections and public well-being worldwide—as the natural progression in an exemplary career of public service. Before establishing AAHRPP in 2001, she served as acting executive director of the National Bioethics Advisory Commission. At the Centers for Disease Control and Prevention, she oversaw research protections for all domestic and international research. Dr. Speers is a graduate of Dickinson College, where she serves on the Board of Trustees and established a scholarship that has benefited numerous international students. She also holds doctoral degrees in psychology and epidemiology from Yale University.
Triple board-certified in internal medicine, hematology and medical oncology, Dr. Mohamad Cherry is medical director of Hematology at Atlantic Health System Cancer Care. He joined Atlantic Hematology Oncology from the University of Oklahoma Health Sciences Center's Stephenson Cancer Center, bringing years of clinical knowledge and expertise. With specialty training from some of the nation's most skilled clinicians, Dr. Cherry attained some of his clinical training at the leukemia department at MD Anderson and his fellowship in hematology/oncology from the University of Oklahoma Health Sciences Center's Stephenson Cancer Center. He performed two residencies - an internal medicine residency at Staten Island University Hospital and a laboratory medicine residency at the American University of Beirut Medical Center in Lebanon. Previously, Dr. Cherry attained his medical degree at Lebanese University and performed his internship at Sacre Coeur Hospital-Lebanese University. He also earned a master of science degree in clinical and translational research from University of Oklahoma College of Public Health. Dr. Cherry remains on staff as clinical associate professor of hematology/oncology at University of Oklahoma Health Sciences Center's Stephenson Cancer Center. He is also the director of its hematology/oncology fellowship program and co-chairs the Academy of Teaching Scholars Faculty Development, Education and Mentoring Committee. Other administrative roles include co-chair of the leukemia working group at the Sarah Cannon Research Institute Blood Cancer Consortium. As a principal investigator of multiple clinical trials, Dr. Cherry has performed groundbreaking research in niche areas that include epigenetics and development of new therapeutics in relapsed and refractory blood cancers. He has developed teaching materials and book chapters, and has lectured both nationally and internationally. Dr. Cherry continues to serves as a mentor and an advisor to fellows, residents and medical students. He contributes to continuing education, public health, and professional development, and has won awards and funding for both his research and his clinical pursuits.
Dr. Angela Alistar is a board-certified medical oncologist with Atlantic Hematology Oncology, Atlantic Medical Group. Dr. Alistar is Medical Director of GI Medical Oncology at Morristown Medical Center where she is also Medical Director of the Phase 1 Breakthrough Treatment Center. Her research focus is related to immuno-oncology and cancer metabolism in gastrointestinal cancer such as: pancreatic tumors, cholangiocarcinoma, colorectal, esophageal, gastric cancer and hepatocellular carcinoma. Her clinical research projects involved active collaborative efforts with other medical departments, such as radiation oncology and surgical oncology, as well as genomics and cancer biology. Recently, she has published in Lancet Oncology the results of a Phase 1 clinical study in pancreatic cancer that are very promising for advancing the field for this disease. This study has shown impressive synergy of a novel agent, CPI -613 in combination with chemotherapy. She is co-leading the national multi-site, randomized study of this promising combination, as well as many other phase 1-3 clinical trials. Dr. Alistar comes to Atlantic Health System from Wake Forest School of Medicine where she had a heavy emphasis on clinical trials and clinical research. At Wake Forest, she led the GI oncology disease oriented team as a gastrointestinal medical oncology physician and researcher, bringing cutting-edge treatments to patients. She designed, secured funding for and conducted five investigator-initiated therapeutic clinical trials, with four of them being phase one. Her work involved maintenance of a sponsor-investigator investigational new drug. She is passionate about Precision Oncology and Immunotherapies and seeks to identify novel treatment strategies for her patients. Past positions at Wake Forest include being a member of the Translational Cancer Genomics Committee, the GI Tumor Board, Internal Medicine Grand Rounds, and the Hepatobiliary Oncology Committee. She is a member of several health care organizations, such as the American Society of Clinical Oncology, the American Society of Hospice and Palliative Care Medicine, and the American Society of Hematology, among many others. As well, she is a member and advisor for several other health care institutions. She was recently awarded the "Danny Danielson Translational Innovation Award" by Hoosier Cancer Research Network for her commitment to clinical research. She received her medical degree from University of Medicine and Pharmacy, Cluj Napoca, Romania and her residency at Englewood Hospital and Medical Center, NJ, where she was chief resident. After her residency, she completed a hematology oncology fellowship at Mount Sinai School of Medicine, Tisch Cancer Institute. She is affiliated with Atlantic Medical Group, and is a participating provider of Atlantic Accountable Care Organization, and sees patients at Morristown Medical Center.
Bonni Lee Guerin, M.D. is a hematologist/oncologist and director of the Breast Cancer Treatment and Prevention Program at Overlook Medical Center, Summit, NJ where she also serves as chair of the Breast Panel, the Multidisciplinary Breast Tumor Board and director of Oncology Education. She is the principal investigator of numerous clinical trials exploring new ways to incorporate the latest advances in the management of breast cancer. She is also actively involved in the delivery of highly-specialized immunotherapy, IL-2, for the treatment of melanoma and kidney cancer. As a medical oncologist with more than 20 years of experience, Dr. Guerin is dedicated to providing the most up to date, cutting edge treatment while looking at each of her patients as an individual. Her philosophy is one of collaboration, working with all members of the care team to provide the best outcome possible. Dr. Guerin believes that compassion and being a good listener, traits she learned from her mother, help tailor a treatment plan that reflects not only the highest order of medical care, but also one that uniquely reflects each and every patient. Dr. Guerin believes it is just as much about living well as it is living long. Dr. Guerin earned her M.D. at SUNY Stony Brook in 1988, continued her residency at Vanderbilt University in Nashville and completed her fellowship in oncology/hematology at University of California San Diego Cancer Center. She is board certified in clinical oncology and internal medicine. Since 2002, Dr. Guerin has served as chair of the Women’s Oncology Forum, Network for Oncology Communication and Research (NOCR) – a national organization. She is a diplomate of the American Society of Clinical Oncology (ASCO) and is a recipient of the Pfizer Award for Excellence in Biochemical Research and a Member of the Expert Panel Consensus Guidelines for Systemic Therapy of Metastatic Renal Cell Carcinoma. She has been named by Castle Connelly as one of NY/Metro Top Doctors for the last 10 years, as well as a Top Doctor for Women's Health. She has recently been honored by Curemonos, a New Jersey non-profit organization dedicated to supporting medically underserved women with breast cancer, was the keynote speaker at the American Cancer Society Relay for Life in Chatham, NJ; and was honored at the Society’s 2019 Diamond Ball, in Woodland Park, NJ. Her interests are in breast cancer, hepatobiliary cancer and immunotherapy.